Weekly Research Analysts’ Ratings Updates for Lycia Therapeutics (LYCA)

Several analysts have recently updated their ratings and price targets for Lycia Therapeutics (NASDAQ: LYCA):

  • 11/17/2026 – Lycia Therapeutics is now covered by Jefferies Financial Group. They set a “buy” rating and a $50.00 price target on the stock.
  • 11/17/2026 – Lycia Therapeutics is now covered by TD Cowen. They set a “buy” rating on the stock.
  • 11/17/2026 – Lycia Therapeutics is now covered by Guggenheim. They set a “buy” rating and a $75.00 price target on the stock.
  • 11/17/2026 – Lycia Therapeutics is now covered by Evercore. They set an “outperform” rating and a $43.00 price target on the stock.
  • 10/31/2026 – Lycia Therapeutics was upgraded by Wall Street Zen to “hold”.

Lycia Therapeutics Price Performance

Shares of LYCA stock opened at $30.92 on Wednesday. Lycia Therapeutics, Inc. has a 1-year low of $22.19 and a 1-year high of $36.49.

Insider Activity at Lycia Therapeutics

In other Lycia Therapeutics news, major shareholder Venrock Healthcare Capital Par acquired 8,305 shares of Lycia Therapeutics stock in a transaction that occurred on Monday, November 2nd. The stock was acquired at an average price of $26.95 per share, with a total value of $223,819.75. Following the purchase, the insider owned 6,858,542 shares in the company, valued at approximately $184,837,706.90. This trade represents a 0.12% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders purchased 2,078,749 shares of company stock valued at $38,526,342.

Lycia Therapeutics is a biotechnology company developing medicines that use its lysosomal targeting chimera (LYTAC) platform to direct disease-related proteins for breakdown inside cells. The approach is designed to address extracellular and cell-surface proteins that may be difficult to target with conventional drug therapies. The company’s work is research and development-focused; it does not have marketed products. Its programs aim to apply targeted protein degradation to conditions including cancer and inflammatory diseases.

Further Reading

Receive News & Ratings for Lycia Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lycia Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.